The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)

Study I8F-MC-GPGN (GPGN), also known as SURPASS-CVOT, is a Phase 3, event-driven, multicenter, international, randomized, double-blind, active comparator, parallel-group study. This study will assess the effect of QW tirzepatide (up to 15 mg) versus dulaglutide (1.5 mg) on CV outcomes when added to the standard of care in patients with T2DM with established cardiovascular disease and elevated risk for MACE.